$RCEL
AVITA Medical, Inc. Stock $rcel

$rcel Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000095017024058619 Filed on May 13, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$15.20M	$11.10M
YoY Change	29.29%	5.25%
Cost Of Revenue	$2.111M	$1.513M
YoY Change	-4.22%	-9.24%
Gross Profit	$13.08M	$9.591M
YoY Change	37.02%	7.97%
Gross Profit Margin	86.11%	86.37%
Selling, General & Admin	$23.82M	$21.60M
YoY Change	47.33%	45.62%
% of Gross Profit	182.06%	225.24%
Research & Development	$4.887M	$5.194M
YoY Change	-3.72%	13.26%
% of Gross Profit	37.35%	54.15%
Depreciation & Amortization	$187.0K	$203.0K
YoY Change	36.5%	50.37%
% of Gross Profit	1.43%	2.12%
Operating Expenses	$28.71M	$26.80M
YoY Change	35.13%	37.98%
Operating Profit	-$15.62M	-$17.21M
YoY Change	39.94%	73.61%
Interest Expense	$1.347M	$1.356M
YoY Change	19142.86%	33800.0%
% of Operating Profit
Other Income/Expense, Net	$1.611M	-$66.00K
YoY Change	101.12%	-109.1%
Pretax Income	-$15.36M	-$18.63M
YoY Change	48.11%	102.7%
Income Tax	$33.00K	$30.00K
% Of Pretax Income
Net Earnings	-$15.39M	-$18.66M
YoY Change	48.24%	102.36%
Net Earnings / Revenue	-101.3%	-168.03%
Basic Earnings Per Share	-$0.60	-$0.73
Diluted Earnings Per Share	-$0.60	-$0.73
COMMON SHARES
Basic Shares Outstanding	25.80M	25.71M
Diluted Shares Outstanding	25.76M	25.64M

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$54.06M	$68.18M
YoY Change	-18.16%	-7.17%
Cash & Equivalents	$17.45M	$16.95M
Short-Term Investments	$36.60M	$51.23M
Other Short-Term Assets	$8.000K	$135.0K
YoY Change	-98.48%	365.52%
Inventory	$6.709M	$7.171M
Prepaid Expenses	$2.159M	$1.216M
Receivables	$8.717M	$7.081M
Other Receivables	$94.00K	$28.00K
Total Short-Term Assets	$72.96M	$85.99M
YoY Change	-5.85%	3.9%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.024M	$4.297M
YoY Change	339.55%	222.36%
Goodwill
YoY Change
Intangibles	$545.0K	$542.0K
YoY Change	19.52%	17.57%
Long-Term Investments
YoY Change
Other Assets	$473.0K	$401.0K
YoY Change	65.96%	74.35%
Total Long-Term Assets	$14.87M	$11.40M
YoY Change	68.29%	15.56%
TOTAL ASSETS
Total Short-Term Assets	$72.96M	$85.99M
Total Long-Term Assets	$14.87M	$11.40M
Total Assets	$87.83M	$97.38M
YoY Change	1.73%	5.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.155M	$4.477M
YoY Change	8.29%	19.32%
Accrued Expenses	$8.444M	$6.706M
YoY Change	23.16%	55.84%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$13.79M	$11.86M
YoY Change	-0.17%	3.27%
LONG-TERM LIABILITIES
Long-Term Debt	$40.99M	$41.30M
YoY Change
Other Long-Term Liabilities	$9.135M	$11.65M
YoY Change	135.86%	225.85%
Total Long-Term Liabilities	$40.99M	$41.30M
YoY Change	958.33%	1055.27%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.79M	$11.86M
Total Long-Term Liabilities	$40.99M	$41.30M
Total Liabilities	$63.51M	$63.99M
YoY Change	285.98%	348.45%
SHAREHOLDERS EQUITY
Retained Earnings	-$332.0M	-$316.6M
YoY Change	17.66%	16.49%
Common Stock	$3.000K	$3.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$23.92M	$32.57M
YoY Change
Total Liabilities & Shareholders Equity	$87.83M	$97.38M
YoY Change	1.73%	5.14%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$15.39M	-$18.66M
YoY Change	48.24%	102.36%
Depreciation, Depletion And Amortization	$187.0K	$203.0K
YoY Change	36.5%	50.37%
Cash From Operating Activities	-$12.78M	-$20.86M
YoY Change	40.42%	129.96%
INVESTING ACTIVITIES
Capital Expenditures	$2.652M	$1.147M
YoY Change	786.96%	303.87%
Acquisitions
YoY Change
Other Investing Activities	$15.08M	$16.21M
YoY Change	-19.17%	-14.99%
Cash From Investing Activities	$12.43M	$15.07M
YoY Change	-32.3%	-19.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	849.0K	631.0K
YoY Change	396.49%	269.01%
NET CHANGE
Cash From Operating Activities	-12.78M	-20.86M
Cash From Investing Activities	12.43M	15.07M
Cash From Financing Activities	849.0K	631.0K
Net Change In Cash	501.0K	-5.167M
YoY Change	-94.69%	-152.27%
FREE CASH FLOW
Cash From Operating Activities	-$12.78M	-$20.86M
Capital Expenditures	$2.652M	$1.147M
Free Cash Flow	-$15.43M	-$22.01M
YoY Change	64.17%	135.24%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-39059
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	AVITA MEDICAL, INC.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	28159 Avenue Stanford
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 220
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Valencia
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91355
CY2024Q1	dei	City Area Code CityAreaCode	(661)
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2024Q1	dei	Trading Symbol TradingSymbol	RCEL
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25799735
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001762303
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2024Q1	us-gaap	Investment Type Extensible Enumeration InvestmentTypeExtensibleEnumeration	http://avitamedical.com/20240331#ContractualMaturitiesMember
CY2023Q4	us-gaap	Investment Type Extensible Enumeration InvestmentTypeExtensibleEnumeration	http://avitamedical.com/20240331#ContractualMaturitiesMember
CY2024Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-39059
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	AVITA MEDICAL, INC.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1021707
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	28159 Avenue Stanford
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 220
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Valencia
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91355
CY2024Q1	dei	City Area Code CityAreaCode	(661)
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	367-9170
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2024Q1	dei	Trading Symbol TradingSymbol	RCEL
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25799735
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16951000
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16951000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22118000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22118000
CY2024Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	51232000
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	66939000
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7081000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7664000
CY2024Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	28000
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	30000
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3523000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1659000
CY2024Q1	us-gaap	Fifo Inventory Amount FIFOInventoryAmount	7171000
CY2023Q4	us-gaap	Fifo Inventory Amount FIFOInventoryAmount	5596000
CY2024Q1	us-gaap	Assets Current AssetsCurrent	85986000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	104006000
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4297000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1877000
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3275000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2440000
CY2024Q1	rcel	Corporate Owned Life Insurance Asset CorporateOwnedLifeInsuranceAsset	2880000
CY2023Q4	rcel	Corporate Owned Life Insurance Asset CorporateOwnedLifeInsuranceAsset	2475000
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	542000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	487000
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	401000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	355000
CY2024Q1	us-gaap	Assets Assets	97381000
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4477000
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3793000
CY2024Q1	rcel	Accrued Wages And Fringe Benefits AccruedWagesAndFringeBenefits	5803000
CY2023Q4	rcel	Accrued Wages And Fringe Benefits AccruedWagesAndFringeBenefits	7972000
CY2024Q1	rcel	Non Qualified Deferred Compensation Plan Liability Current NonQualifiedDeferredCompensationPlanLiabilityCurrent	429000
CY2023Q4	rcel	Non Qualified Deferred Compensation Plan Liability Current NonQualifiedDeferredCompensationPlanLiabilityCurrent	168000
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1153000
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1266000
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	11862000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13199000
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	41301000
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	39812000
CY2024Q1	rcel	Non Qualified Deferred Compensation Plan Liability NonQualifiedDeferredCompensationPlanLiability	3913000
CY2023Q4	rcel	Non Qualified Deferred Compensation Plan Liability NonQualifiedDeferredCompensationPlanLiability	3663000
CY2024Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	349000
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	357000
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2532000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1702000
CY2024Q1	rcel	Warrant Liability WarrantLiability	4028000
CY2023Q4	rcel	Warrant Liability WarrantLiability	3158000
CY2024Q1	us-gaap	Liabilities Liabilities	63985000
CY2023Q4	us-gaap	Liabilities Liabilities	61891000
CY2024Q1	rcel	Non Qualified Deferred Compensation Plan Share Awards NonQualifiedDeferredCompensationPlanShareAwards	827000
CY2024Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	51232000
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	66939000
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7081000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7664000
CY2024Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	28000
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	30000
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3523000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1659000
CY2024Q1	us-gaap	Fifo Inventory Amount FIFOInventoryAmount	7171000
CY2023Q4	us-gaap	Fifo Inventory Amount FIFOInventoryAmount	5596000
CY2024Q1	us-gaap	Assets Current AssetsCurrent	85986000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	104006000
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4297000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1877000
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3275000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2440000
CY2024Q1	rcel	Corporate Owned Life Insurance Asset CorporateOwnedLifeInsuranceAsset	2880000
CY2023Q4	rcel	Corporate Owned Life Insurance Asset CorporateOwnedLifeInsuranceAsset	2475000
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	542000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	487000
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	401000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	355000
CY2024Q1	us-gaap	Assets Assets	97381000
CY2023Q4	us-gaap	Assets Assets	111640000
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4477000
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3793000
CY2024Q1	rcel	Accrued Wages And Fringe Benefits AccruedWagesAndFringeBenefits	5803000
CY2023Q4	rcel	Accrued Wages And Fringe Benefits AccruedWagesAndFringeBenefits	7972000
CY2024Q1	rcel	Non Qualified Deferred Compensation Plan Liability Current NonQualifiedDeferredCompensationPlanLiabilityCurrent	429000
CY2023Q4	rcel	Non Qualified Deferred Compensation Plan Liability Current NonQualifiedDeferredCompensationPlanLiabilityCurrent	168000
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1153000
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1266000
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	11862000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13199000
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	41301000
CY2024Q1	rcel	Non Qualified Deferred Compensation Plan Liability NonQualifiedDeferredCompensationPlanLiability	3913000
CY2023Q4	rcel	Non Qualified Deferred Compensation Plan Liability NonQualifiedDeferredCompensationPlanLiability	3663000
CY2024Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	349000
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	357000
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2532000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1702000
CY2023Q4	rcel	Warrant Liability WarrantLiability	3158000
CY2024Q1	us-gaap	Liabilities Liabilities	63985000
CY2023Q4	us-gaap	Liabilities Liabilities	61891000
CY2024Q1	rcel	Non Qualified Deferred Compensation Plan Share Awards NonQualifiedDeferredCompensationPlanShareAwards	827000
CY2023Q4	rcel	Non Qualified Deferred Compensation Plan Share Awards NonQualifiedDeferredCompensationPlanShareAwards	693000
CY2023Q4	rcel	Non Qualified Deferred Compensation Plan Share Awards NonQualifiedDeferredCompensationPlanShareAwards	693000
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25789051
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25789051
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25682078
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25682078
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	3000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	3000
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2024Q1	rcel	Common Stock Held By Non Qualified Deferred Compensation Plan CommonStockHeldByNonQualifiedDeferredCompensationPlan	-944000
CY2023Q4	rcel	Common Stock Held By Non Qualified Deferred Compensation Plan CommonStockHeldByNonQualifiedDeferredCompensationPlan	-1130000
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	353205000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	350039000
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3068000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1887000
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-316627000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-297969000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	32569000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	49056000
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	97381000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	111640000
CY2024Q1	us-gaap	Revenues Revenues	11104000
CY2023Q1	us-gaap	Revenues Revenues	10550000
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	1513000
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	1667000
CY2024Q1	us-gaap	Gross Profit GrossProfit	9591000
CY2023Q1	us-gaap	Gross Profit GrossProfit	8883000
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	627000
CY2024Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	12640000
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6540000
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8963000
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8295000
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5194000
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4586000
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25789051
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25789051
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25682078
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25682078
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	3000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	3000
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2024Q1	rcel	Common Stock Held By Non Qualified Deferred Compensation Plan CommonStockHeldByNonQualifiedDeferredCompensationPlan	-944000
CY2023Q4	rcel	Common Stock Held By Non Qualified Deferred Compensation Plan CommonStockHeldByNonQualifiedDeferredCompensationPlan	-1130000
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	353205000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	350039000
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3068000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1887000
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-316627000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-297969000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	32569000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	49056000
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	97381000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	111640000
CY2024Q1	us-gaap	Revenues Revenues	11104000
CY2023Q1	us-gaap	Revenues Revenues	10550000
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	1513000
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	1667000
CY2024Q1	us-gaap	Gross Profit GrossProfit	9591000
CY2023Q1	us-gaap	Gross Profit GrossProfit	8883000
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	627000
CY2024Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	12640000
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6540000
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8963000
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8295000
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5194000
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4586000
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	26797000
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	26797000
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	19421000
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-17206000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9911000
CY2024Q1	us-gaap	Interest Expense InterestExpense	1356000
CY2023Q1	us-gaap	Interest Expense InterestExpense	4000
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-66000
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	725000
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18628000
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9190000
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	30000
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	30000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-18658000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-9220000
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25637783
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25637783
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25202088
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25202088
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-18658000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-9220000
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-11000
CY2024Q1	rcel	Change In Fair Value Due To Credit Risk On Long Term Debt ChangeInFairValueDueToCreditRiskOnLongTermDebt	-1092000
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-89000
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8989000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	49056000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-18658000
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2585000
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	631000
CY2024Q1	rcel	Distribution Diversification Of Common Stock Held By The Nqdc Plan DistributionDiversificationOfCommonStockHeldByTheNqdcPlan	264000
CY2024Q1	rcel	Change In Redemption Value Of Share Awards In Nqdc Plan ChangeInRedemptionValueOfShareAwardsInNQDCPlan	-128000
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-89000
CY2024Q1	rcel	Change In Fair Value Due To Credit Risk On Long Term Debt ChangeInFairValueDueToCreditRiskOnLongTermDebt	-1092000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	32569000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	84740000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-9220000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2197000
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	171000
CY2023Q1	rcel	Change In Redemption Value Of Share Awards In Nqdc Plan ChangeInRedemptionValueOfShareAwardsInNQDCPlan	-558000
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	231000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	77561000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-18658000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-9220000
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	19421000
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-17206000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9911000
CY2024Q1	us-gaap	Interest Expense InterestExpense	1356000
CY2023Q1	us-gaap	Interest Expense InterestExpense	4000
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-66000
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	725000
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18628000
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9190000
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	30000
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	30000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-18658000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-9220000
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25637783
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25637783
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25202088
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25202088
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-18658000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-9220000
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-11000
CY2024Q1	rcel	Change In Fair Value Due To Credit Risk On Long Term Debt ChangeInFairValueDueToCreditRiskOnLongTermDebt	-1092000
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-89000
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	242000
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19839000
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8989000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	49056000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-18658000
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2585000
CY2024Q1	rcel	Distribution Diversification Of Common Stock Held By The Nqdc Plan DistributionDiversificationOfCommonStockHeldByTheNqdcPlan	264000
CY2024Q1	rcel	Change In Redemption Value Of Share Awards In Nqdc Plan ChangeInRedemptionValueOfShareAwardsInNQDCPlan	-128000
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-89000
CY2024Q1	rcel	Change In Fair Value Due To Credit Risk On Long Term Debt ChangeInFairValueDueToCreditRiskOnLongTermDebt	-1092000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	32569000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	84740000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-9220000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2197000
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	171000
CY2023Q1	rcel	Change In Redemption Value Of Share Awards In Nqdc Plan ChangeInRedemptionValueOfShareAwardsInNQDCPlan	-558000
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	231000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	77561000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-18658000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-9220000
CY2024Q1	rcel	Change In Fair Value Of Long Term Debt ChangeInFairValueOfLongTermDebt	397000
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	870000
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	203000
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	135000
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2591000
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2640000
CY2024Q1	rcel	Non Cash Lease Expense NonCashLeaseExpense	214000
CY2023Q1	rcel	Non Cash Lease Expense NonCashLeaseExpense	167000
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2000
CY2024Q1	rcel	Excess And Obsolete Inventory Related Charges ExcessAndObsoleteInventoryRelatedCharges	-83000
CY2023Q1	rcel	Excess And Obsolete Inventory Related Charges ExcessAndObsoleteInventoryRelatedCharges	-67000
CY2023Q1	rcel	Estimated Deferred Costs EstimatedDeferredCosts	-64000
CY2023Q1	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	85000
CY2024Q1	us-gaap	Provision For Loan And Lease Losses ProvisionForLoanAndLeaseLosses	80000
CY2023Q1	us-gaap	Provision For Loan And Lease Losses ProvisionForLoanAndLeaseLosses	172000
CY2024Q1	rcel	Amortization Of Premium Of Marketable Securities AmortizationOfPremiumOfMarketableSecurities	-677000
CY2023Q1	rcel	Amortization Of Premium Of Marketable Securities AmortizationOfPremiumOfMarketableSecurities	-328000
CY2024Q1	rcel	Non Cash Changes In Fair Value Of Non Qualified Deferred Compensation Plan NonCashChangesInFairValueOfNonQualifiedDeferredCompensationPlan	-278000
CY2023Q1	rcel	Non Cash Changes In Fair Value Of Non Qualified Deferred Compensation Plan NonCashChangesInFairValueOfNonQualifiedDeferredCompensationPlan	-610000
CY2024Q1	rcel	Increase Decrease In Trade And Other Receivables IncreaseDecreaseInTradeAndOtherReceivables	503000
CY2023Q1	rcel	Increase Decrease In Trade And Other Receivables IncreaseDecreaseInTradeAndOtherReceivables	-1158000
CY2024Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-2000
CY2023Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-382000
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1864000
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-12000
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1659000
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	754000
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-224000
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-156000
CY2024Q1	rcel	Increase Decrease In Corporate Owned Life Insurance Asset IncreaseDecreaseInCorporateOwnedLifeInsuranceAsset	215000
CY2023Q1	rcel	Increase Decrease In Corporate Owned Life Insurance Asset IncreaseDecreaseInCorporateOwnedLifeInsuranceAsset	526000
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	46000
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	109000
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-763000
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	778000
CY2024Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-2170000
CY2023Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-2957000
CY2024Q1	rcel	Increase Decrease In Current Non Qualified Deferred Compensation Liability IncreaseDecreaseInCurrentNonQualifiedDeferredCompensationLiability	473000
CY2023Q1	rcel	Increase Decrease In Current Non Qualified Deferred Compensation Liability IncreaseDecreaseInCurrentNonQualifiedDeferredCompensationLiability	748000
CY2024Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-109000
CY2023Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	958000
CY2024Q1	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	-165000
CY2023Q1	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	-237000
CY2024Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-8000
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-316000
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20864000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9073000
CY2024Q1	rcel	Change In Fair Value Of Long Term Debt ChangeInFairValueOfLongTermDebt	397000
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	870000
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	135000
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2591000
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2640000
CY2024Q1	rcel	Non Cash Lease Expense NonCashLeaseExpense	214000
CY2023Q1	rcel	Non Cash Lease Expense NonCashLeaseExpense	167000
CY2024Q1	rcel	Excess And Obsolete Inventory Related Charges ExcessAndObsoleteInventoryRelatedCharges	-83000
CY2023Q1	rcel	Excess And Obsolete Inventory Related Charges ExcessAndObsoleteInventoryRelatedCharges	-67000
CY2023Q1	rcel	Estimated Deferred Costs EstimatedDeferredCosts	-64000
CY2023Q1	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	85000
CY2024Q1	us-gaap	Provision For Loan And Lease Losses ProvisionForLoanAndLeaseLosses	80000
CY2023Q1	us-gaap	Provision For Loan And Lease Losses ProvisionForLoanAndLeaseLosses	172000
CY2024Q1	rcel	Amortization Of Premium Of Marketable Securities AmortizationOfPremiumOfMarketableSecurities	-677000
CY2023Q1	rcel	Amortization Of Premium Of Marketable Securities AmortizationOfPremiumOfMarketableSecurities	-328000
CY2024Q1	rcel	Non Cash Changes In Fair Value Of Non Qualified Deferred Compensation Plan NonCashChangesInFairValueOfNonQualifiedDeferredCompensationPlan	-278000
CY2023Q1	rcel	Non Cash Changes In Fair Value Of Non Qualified Deferred Compensation Plan NonCashChangesInFairValueOfNonQualifiedDeferredCompensationPlan	-610000
CY2024Q1	rcel	Increase Decrease In Trade And Other Receivables IncreaseDecreaseInTradeAndOtherReceivables	503000
CY2023Q1	rcel	Increase Decrease In Trade And Other Receivables IncreaseDecreaseInTradeAndOtherReceivables	-1158000
CY2024Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-2000
CY2023Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-382000
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1864000
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-12000
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1659000
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	754000
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-224000
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	46000
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	109000
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-763000
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	778000
CY2024Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-2170000
CY2023Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-2957000
CY2024Q1	rcel	Increase Decrease In Current Non Qualified Deferred Compensation Liability IncreaseDecreaseInCurrentNonQualifiedDeferredCompensationLiability	473000
CY2023Q1	rcel	Increase Decrease In Current Non Qualified Deferred Compensation Liability IncreaseDecreaseInCurrentNonQualifiedDeferredCompensationLiability	748000
CY2024Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-109000
CY2024Q1	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	-165000
CY2023Q1	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	-237000
CY2024Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-8000
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-316000
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20864000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9073000
CY2024Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2904000
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	5183000
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	19200000
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	24271000
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1147000
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	284000
CY2024Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2904000
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	5183000
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	19200000
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	24271000
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1147000
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	284000
CY2024Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	83000
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	17000
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	15066000
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18787000
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	631000
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	171000
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	631000
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	171000
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5167000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9886000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22118000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18164000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16951000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28050000
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	17
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	9
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	1355
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	4
CY2024Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	74
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	9
CY2024Q1	rcel	Right Of Use Asset Obtained In Exchange For Lease Liabilities RightOfUseAssetObtainedInExchangeForLeaseLiabilities	1053
CY2024Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	51225000
CY2024Q1	rcel	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent	11000
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	17000
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18787000
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	631000
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	171000
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	631000
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	171000
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5167000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9886000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22118000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18164000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16951000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28050000
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	17
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	9
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	1355
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	4
CY2024Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	74
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	9
CY2024Q1	rcel	Right Of Use Asset Obtained In Exchange For Lease Liabilities RightOfUseAssetObtainedInExchangeForLeaseLiabilities	1053
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the accompanying Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts (including estimate of the average selling price for PermeaDerm sales, allowance for credit losses, reserves for inventory excess and obsolescence, carrying value of long-lived assets, the useful lives of long-lived assets, accounting for marketable securities, income taxes, fair value of the debt, fair value of warrants and stock-based compensation) and related disclosures. Estimates have been prepared on the basis of the current and available information. However, actual results could differ from estimated amounts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2024Q1	rcel	Cash At Deposit Institutions CashAtDepositInstitutions	4900000
CY2023Q4	rcel	Cash At Deposit Institutions CashAtDepositInstitutions	10700000
CY2024Q1	rcel	Cash In Foreign Institutions CashInForeignInstitutions	0
CY2023Q4	rcel	Cash In Foreign Institutions CashInForeignInstitutions	69000
CY2024Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	12000000
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	11400000
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables and debt and other liabilities. As of March 31, 2024 and December 31, 2023, substantially all the Company’s cash was deposited in accounts at financial institutions, and amounts exceed federally insured limits and are subject to the risk of bank failure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024 and December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> single commercial customer accounted for more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of net accounts receivable or more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of revenues for the three-months ended March 31, 2024 and 2023.</span></p>
CY2024Q1	rcel	Cash At Deposit Institutions CashAtDepositInstitutions	4900000
CY2023Q4	rcel	Cash At Deposit Institutions CashAtDepositInstitutions	10700000
CY2024Q1	rcel	Cash In Foreign Institutions CashInForeignInstitutions	0
CY2023Q4	rcel	Cash In Foreign Institutions CashInForeignInstitutions	69000
CY2024Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	12000000
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	11400000
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables and debt and other liabilities. As of March 31, 2024 and December 31, 2023, substantially all the Company’s cash was deposited in accounts at financial institutions, and amounts exceed federally insured limits and are subject to the risk of bank failure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024 and December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> single commercial customer accounted for more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of net accounts receivable or more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of revenues for the three-months ended March 31, 2024 and 2023.</span></p>
CY2024Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	51225000
CY2024Q1	rcel	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent	11000
CY2024Q1	rcel	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent	4000
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	51232000
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	66844000
CY2023Q4	rcel	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent	100000
CY2023Q4	rcel	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent	5000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	66939000
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	51225000
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	51232000
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	66844000
CY2023Q4	rcel	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent	100000
CY2023Q4	rcel	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent	5000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	66939000
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	51225000
CY2024Q1	rcel	Available For Sale Securities Debt Maturities Within One Year Carrying Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearCarryingValue	51232000
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	66844000
CY2023Q4	rcel	Available For Sale Securities Debt Maturities Within One Year Carrying Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearCarryingValue	66939000
CY2024Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-7000
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-95000
CY2024Q1	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments	0
CY2023Q1	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments	0
CY2024Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	382000
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	390000
CY2024Q1	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0
CY2023Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0
CY2024Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	382000
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	390000
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	40000000
CY2024Q1	rcel	Debt Instrument Outstanding Amount Addition Reduction To Liability DebtInstrumentOutstandingAmountAdditionReductionToLiability	1300000
CY2023Q4	rcel	Debt Instrument Outstanding Amount Addition Reduction To Liability DebtInstrumentOutstandingAmountAdditionReductionToLiability	-188000
CY2024Q1	rcel	Increase In Operating Lease Rou Assets And Operating Lease Liabilities IncreaseInOperatingLeaseRouAssetsAndOperatingLeaseLiabilities	1300000
CY2024Q1	rcel	Available For Sale Securities Debt Maturities Within One Year Carrying Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearCarryingValue	51232000
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	66844000
CY2023Q4	rcel	Available For Sale Securities Debt Maturities Within One Year Carrying Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearCarryingValue	66939000
CY2024Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-7000
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-95000
CY2024Q1	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments	0
CY2023Q1	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments	0
CY2024Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	390000
CY2024Q1	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0
CY2023Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0
CY2024Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	382000
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	390000
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	40000000
CY2024Q1	rcel	Debt Instrument Outstanding Amount Addition Reduction To Liability DebtInstrumentOutstandingAmountAdditionReductionToLiability	1300000
CY2023Q4	rcel	Debt Instrument Outstanding Amount Addition Reduction To Liability DebtInstrumentOutstandingAmountAdditionReductionToLiability	-188000
CY2024Q1	rcel	Increase In Operating Lease Rou Assets And Operating Lease Liabilities IncreaseInOperatingLeaseRouAssetsAndOperatingLeaseLiabilities	1300000
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	296000
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	198000
CY2024Q1	us-gaap	Variable Lease Cost VariableLeaseCost	35000
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	13000
CY2024Q1	us-gaap	Lease Cost LeaseCost	331000
CY2023Q1	us-gaap	Lease Cost LeaseCost	211000
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	293000
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	205000
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	296000
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	198000
CY2024Q1	us-gaap	Variable Lease Cost VariableLeaseCost	35000
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	13000
CY2024Q1	us-gaap	Lease Cost LeaseCost	331000
CY2023Q1	us-gaap	Lease Cost LeaseCost	211000
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	293000
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	205000
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3275000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2440000
CY2024Q1	rcel	Right Of Use Assets RightOfUseAssets	3275000
CY2023Q4	rcel	Right Of Use Assets RightOfUseAssets	2440000
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	903000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	895000
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2532000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1702000
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3435000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2597000
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y5M15D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M21D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0942
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0875
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3275000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2440000
CY2024Q1	rcel	Right Of Use Assets RightOfUseAssets	3275000
CY2023Q4	rcel	Right Of Use Assets RightOfUseAssets	2440000
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	903000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	895000
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2532000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1702000
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3435000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2597000
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y5M15D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M21D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0942
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0875
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	891000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1165000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1125000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	657000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	190000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4028000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	593000
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3435000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	891000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	657000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	190000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4028000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	593000
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3435000
CY2024Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2693000
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3683000
CY2024Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	446000
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	878000
CY2024Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4032000
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1035000
CY2024Q1	us-gaap	Inventory Net InventoryNet	7171000
CY2023Q4	us-gaap	Inventory Net InventoryNet	5596000
CY2024Q1	rcel	Excess And Obsolete Inventory Related Charges ExcessAndObsoleteInventoryRelatedCharges	-83000
CY2023Q1	rcel	Excess And Obsolete Inventory Related Charges ExcessAndObsoleteInventoryRelatedCharges	-67000
CY2024Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	688000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	146000
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	542000
CY2023Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	616000
CY2024Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2693000
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3683000
CY2024Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	446000
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	878000
CY2024Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4032000
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1035000
CY2024Q1	us-gaap	Inventory Net InventoryNet	7171000
CY2023Q4	us-gaap	Inventory Net InventoryNet	5596000
CY2024Q1	rcel	Excess And Obsolete Inventory Related Charges ExcessAndObsoleteInventoryRelatedCharges	-83000
CY2023Q1	rcel	Excess And Obsolete Inventory Related Charges ExcessAndObsoleteInventoryRelatedCharges	-67000
CY2024Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	688000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	146000
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	542000
CY2023Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	616000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	129000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	487000
CY2024Q1	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0
CY2023Q1	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	17000
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	129000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	487000
CY2024Q1	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0
CY2023Q1	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	17000
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	48000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	64000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	51000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	37000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	37000
CY2024Q1	rcel	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	251000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	488000
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2618000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2432000
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4297000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1877000
CY2024Q1	us-gaap	Depreciation Depreciation	186000
CY2023Q1	us-gaap	Depreciation Depreciation	126000
CY2023Q1	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2024Q1	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3523000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1659000
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1153000
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1266000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	48000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	64000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	51000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	37000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	37000
CY2024Q1	rcel	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	251000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	488000
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2618000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2432000
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4297000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1877000
CY2024Q1	us-gaap	Depreciation Depreciation	186000
CY2023Q1	us-gaap	Depreciation Depreciation	126000
CY2023Q1	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2024Q1	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1216000
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1376000
CY2024Q1	rcel	Unsettled Investment Receivable UnsettledInvestmentReceivable	1000000
CY2024Q1	rcel	Amounts Due From Stedical AmountsDueFromStedical	941000
CY2024Q1	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	182000
CY2023Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	227000
CY2024Q1	rcel	Lease Deposits Current LeaseDepositsCurrent	49000
CY2023Q4	rcel	Lease Deposits Current LeaseDepositsCurrent	38000
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	135000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	18000
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1216000
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1376000
CY2024Q1	rcel	Unsettled Investment Receivable UnsettledInvestmentReceivable	1000000
CY2024Q1	rcel	Amounts Due From Stedical AmountsDueFromStedical	941000
CY2024Q1	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	182000
CY2023Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	227000
CY2024Q1	rcel	Lease Deposits Current LeaseDepositsCurrent	49000
CY2023Q4	rcel	Lease Deposits Current LeaseDepositsCurrent	38000
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	135000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	18000
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3523000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1659000
CY2024Q1	us-gaap	Deposit Assets DepositAssets	151000
CY2023Q4	us-gaap	Deposit Assets DepositAssets	155000
CY2024Q1	rcel	Other Long Term Assets Long Term Prepaids OtherLongTermAssetsLongTermPrepaids	135000
CY2023Q4	rcel	Other Long Term Assets Long Term Prepaids OtherLongTermAssetsLongTermPrepaids	148000
CY2024Q1	rcel	Other Long Term Assets Non Current OtherLongTermAssetsNonCurrent	115000
CY2023Q4	rcel	Other Long Term Assets Non Current OtherLongTermAssetsNonCurrent	52000
CY2024Q1	rcel	Other Long Term Assets OtherLongTermAssets	401000
CY2023Q4	rcel	Other Long Term Assets OtherLongTermAssets	355000
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	903000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	895000
CY2024Q1	rcel	Cosmotec Deferred Revenue CosmotecDeferredRevenue	33000
CY2023Q4	rcel	Cosmotec Deferred Revenue CosmotecDeferredRevenue	33000
CY2024Q1	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	217000
CY2023Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	338000
CY2024Q1	us-gaap	Deposit Assets DepositAssets	151000
CY2023Q4	us-gaap	Deposit Assets DepositAssets	155000
CY2024Q1	rcel	Other Long Term Assets Long Term Prepaids OtherLongTermAssetsLongTermPrepaids	135000
CY2023Q4	rcel	Other Long Term Assets Long Term Prepaids OtherLongTermAssetsLongTermPrepaids	148000
CY2024Q1	rcel	Other Long Term Assets Non Current OtherLongTermAssetsNonCurrent	115000
CY2023Q4	rcel	Other Long Term Assets Non Current OtherLongTermAssetsNonCurrent	52000
CY2024Q1	rcel	Other Long Term Assets OtherLongTermAssets	401000
CY2023Q4	rcel	Other Long Term Assets OtherLongTermAssets	355000
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	903000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	895000
CY2024Q1	rcel	Cosmotec Deferred Revenue CosmotecDeferredRevenue	33000
CY2023Q4	rcel	Cosmotec Deferred Revenue CosmotecDeferredRevenue	33000
CY2024Q1	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	217000
CY2023Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	338000
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1153000
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1266000
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2024Q1	us-gaap	Revenues Revenues	11104000
CY2023Q1	us-gaap	Revenues Revenues	10550000
CY2024Q1	us-gaap	Revenues Revenues	11104000
CY2023Q1	us-gaap	Revenues Revenues	10550000
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	1513000
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	1667000
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	20904
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	214228
CY2023Q2	rcel	Employee Stock Purchases Plan Effective Date EmployeeStockPurchasesPlanEffectiveDate	2023-07-01
CY2023Q2	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	1000000
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	132841
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3541384
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1030283
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3541384
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	235132
CY2024Q1	us-gaap	Revenues Revenues	11104000
CY2023Q1	us-gaap	Revenues Revenues	10550000
CY2024Q1	us-gaap	Revenues Revenues	11104000
CY2023Q1	us-gaap	Revenues Revenues	10550000
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	1513000
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	1667000
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25789051
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25789051
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25682078
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25682078
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q1	rcel	Share Based Compensation Expense Related To Equity And Employee Stock Purchase Plan Expense ShareBasedCompensationExpenseRelatedToEquityAndEmployeeStockPurchasePlanExpense	2600000
CY2023Q1	rcel	Share Based Compensation Expense Related To Equity And Employee Stock Purchase Plan Expense ShareBasedCompensationExpenseRelatedToEquityAndEmployeeStockPurchasePlanExpense	2600000
CY2024Q1	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	0
CY2023Q1	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	0
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2591000
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2640000
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25789051
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25789051
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25682078
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25682078
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q1	rcel	Share Based Compensation Expense Related To Equity And Employee Stock Purchase Plan Expense ShareBasedCompensationExpenseRelatedToEquityAndEmployeeStockPurchasePlanExpense	2600000
CY2023Q1	rcel	Share Based Compensation Expense Related To Equity And Employee Stock Purchase Plan Expense ShareBasedCompensationExpenseRelatedToEquityAndEmployeeStockPurchasePlanExpense	2600000
CY2024Q1	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	0
CY2023Q1	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	0
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2591000
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2640000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2690158
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1156000
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	106973
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	64960
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	83893
CY2024Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2024Q1	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	835000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2690158
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1156000
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	106973
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	64960
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	132841
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3541384
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1030283
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3541384
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	235132
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	20904
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	214228
CY2023Q2	rcel	Employee Stock Purchases Plan Effective Date EmployeeStockPurchasesPlanEffectiveDate	2023-07-01
CY2023Q2	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	1000000
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	30000
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	30000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-18658000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-9220000
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25638000
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25638000
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25202000
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25202000
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2023Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	3800000
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	30000
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	30000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-18658000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-9220000
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25638000
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25638000
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25202000
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25202000
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	83893
CY2024Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2024Q1	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	835000
CY2023Q1	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	423000
CY2024Q1	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	4300000
CY2023Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	3800000
CY2024Q1	rcel	Payout Of Deferred Compensation Liability PayoutOfDeferredCompensationLiability	215000
CY2023Q1	rcel	Payout Of Deferred Compensation Liability PayoutOfDeferredCompensationLiability	0
CY2024Q1	us-gaap	Deferred Compensation Arrangement With Individual Shares Issued DeferredCompensationArrangementWithIndividualSharesIssued	117326
CY2023	us-gaap	Deferred Compensation Arrangement With Individual Shares Issued DeferredCompensationArrangementWithIndividualSharesIssued	81052
CY2024Q1	rcel	Deferred Compensation Arrangement With Individual Shares Vested DeferredCompensationArrangementWithIndividualSharesVested	83893
CY2023	rcel	Deferred Compensation Arrangement With Individual Shares Vested DeferredCompensationArrangementWithIndividualSharesVested	99106
CY2024Q1	rcel	Deferred Compensation Arrangement With Individual Vested Redemption Value DeferredCompensationArrangementWithIndividualVestedRedemptionValue	944000
CY2023	rcel	Deferred Compensation Arrangement With Individual Vested Redemption Value DeferredCompensationArrangementWithIndividualVestedRedemptionValue	1100000
CY2023Q1	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	423000
CY2024Q1	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	4300000
CY2024Q1	rcel	Payout Of Deferred Compensation Liability PayoutOfDeferredCompensationLiability	215000
CY2023Q1	rcel	Payout Of Deferred Compensation Liability PayoutOfDeferredCompensationLiability	0
CY2024Q1	us-gaap	Deferred Compensation Arrangement With Individual Shares Issued DeferredCompensationArrangementWithIndividualSharesIssued	117326
CY2023	us-gaap	Deferred Compensation Arrangement With Individual Shares Issued DeferredCompensationArrangementWithIndividualSharesIssued	81052
CY2024Q1	rcel	Deferred Compensation Arrangement With Individual Shares Vested DeferredCompensationArrangementWithIndividualSharesVested	83893
CY2023	rcel	Deferred Compensation Arrangement With Individual Shares Vested DeferredCompensationArrangementWithIndividualSharesVested	99106
CY2024Q1	rcel	Deferred Compensation Arrangement With Individual Vested Redemption Value DeferredCompensationArrangementWithIndividualVestedRedemptionValue	944000
CY2023	rcel	Deferred Compensation Arrangement With Individual Vested Redemption Value DeferredCompensationArrangementWithIndividualVestedRedemptionValue	1100000

Files In Submission

Name	View Source	Status
0000950170-24-058619-index-headers.html	Edgar Link	pending
0000950170-24-058619-index.html	Edgar Link	pending
0000950170-24-058619.txt	Edgar Link	pending
0000950170-24-058619-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img179644470_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
rcel-20240331.htm	Edgar Link	pending
rcel-20240331.xsd	Edgar Link	pending
rcel-ex10_1.htm	Edgar Link	pending
rcel-ex10_2.htm	Edgar Link	pending
rcel-ex10_3.htm	Edgar Link	pending
rcel-ex31_1.htm	Edgar Link	pending
rcel-ex31_2.htm	Edgar Link	pending
rcel-ex32.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
rcel-20240331_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RCEL
AVITA Medical, Inc. Stock $rcel

2024 Q2 Form 10-Q Financial Statement

#000095017024058619 Filed on May 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RCEL AVITA Medical, Inc. Stock $rcel

2024 Q2 Form 10-Q Financial Statement

#000095017024058619 Filed on May 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RCEL
AVITA Medical, Inc. Stock $rcel